Rick Stevens

Rick Stevens

Auto-generated profile, based on publicly available information

Rick Stevens

Argonne National Laboratory, Lemont, USA and University of Chicago, Lemont, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2022 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
RORobert D Olson
Robert D Olson
RARida Assaf
Rida Assaf
TBThomas Brettin
Thomas Brettin
NCNeal Conrad
Neal Conrad
CCClark Cucinell
Clark Cucinell
RSRick L Stevens
Rick L Stevens
The National Institute of Allergy and Infectious Diseases (NIAID) established the Bioinformatics Resource Center (BRC) program to assist researchers with analyzing the growing body of genome sequence and other omics-related data. In this report, we describe the merger of the PAThosystems Resource Integration Center (PATRIC), the Influenza Research Database (IRD) and the Virus Pathogen Database and Analysis Resource (ViPR) BRCs to form the Bacterial and Viral Bioinformatics Resource Center (BV-BRC) https://www.bv-brc.org/. The combined BV-BRC leverages the functionality of the bacterial and viral resources to provide a unified data model, enhanced web-based visualization and analysis tools, bioinformatics services, and a powerful suite of command line tools that benefit the bacterial and viral research communities.

14 June 2016 in Scientific Reports
Verified
Journal Article
Open access
JDJames J. Davis
James J. Davis
SBSébastien Boisvert
Sébastien Boisvert
TBThomas Brettin
Thomas Brettin
RKRonald W. Kenyon
Ronald W. Kenyon
CMChunhong Mao
Chunhong Mao
RSRick Stevens
Rick Stevens
The emergence and spread of antimicrobial resistance (AMR) mechanisms in bacterial pathogens, coupled with the dwindling number of effective antibiotics, has created a global health crisis. Being able to identify the genetic mechanisms of AMR and predict the resistance phenotypes of bacterial pathogens prior to culturing could inform clinical decision-making and improve reaction time. At PATRIC (http://patricbrc.org/), we have been collecting bacterial genomes with AMR metadata for several years. In order to advance phenotype prediction and the identification of genomic regions relating to AMR, we have updated the PATRIC FTP server to enable access to genomes that are binned by their AMR phenotypes, as well as metadata including minimum inhibitory concentrations. Using this infrastructure, we custom built AdaBoost (adaptive boosting) machine learning classifiers for identifying carbapenem resistance in Acinetobacter baumannii, methicillin resistance in Staphylococcus aureus, and beta-lactam and co-trimoxazole resistance in Streptococcus pneumoniae with accuracies ranging from 88-99%. We also did this for isoniazid, kanamycin, ofloxacin, rifampicin, and streptomycin resistance in Mycobacterium tuberculosis, achieving accuracies ranging from 71-88%. This set of classifiers has been used to provide an initial framework for species-specific AMR phenotype and genomic feature prediction in the RAST and PATRIC annotation services.

11 August 2021 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
MVMargo VanOeffelen
Margo VanOeffelen
MNMarcus Nguyen
Marcus Nguyen
DADerya Aytan-Aktug
Derya Aytan-Aktug
TBThomas Brettin
Thomas Brettin
EDEmily M Dietrich
Emily M Dietrich
JDJames J. Davis
James J. Davis
Antimicrobial resistance (AMR) is a major global health threat that affects millions of people each year. Funding agencies worldwide and the global research community have expended considerable capital and effort tracking the evolution and spread of AMR by isolating and sequencing bacterial strains and performing antimicrobial susceptibility testing (AST). For the last several years, we have been capturing these efforts by curating data from the literature and data resources and building a set of assembled bacterial genome sequences that are paired with laboratory-derived AST data. This collection currently contains AST data for over 67 000 genomes encompassing approximately 40 genera and over 100 species. In this paper, we describe the characteristics of this collection, highlighting areas where sampling is comparatively deep or shallow, and showing areas where attention is needed from the research community to improve sampling and tracking efforts. In addition to using the data to track the evolution and spread of AMR, it also serves as a useful starting point for building machine learning models for predicting AMR phenotypes. We demonstrate this by describing two machine learning models that are built from the entire dataset to show where the predictive power is comparatively high or low. This AMR metadata collection is freely available and maintained on the Bacterial and Viral Bioinformatics Center (BV-BRC) FTP site ftp://ftp.bvbrc.org/RELEASE_NOTES/PATRIC_genomes_AMR.txt.

18 November 2025 in Nucleic Acids Research
Verified
Journal Article
Closed access
MSMaulik Shukla
Maulik Shukla
AWAlice R Wattam
Alice R Wattam
AAAntonio Aleman
Antonio Aleman
RBRoshni Bhattacharya
Roshni Bhattacharya
NBNicole Bowers
Nicole Bowers
RSRick L Stevens
Rick L Stevens
The Bacterial and Viral Bioinformatics Resource Center (BV-BRC; https://www.bv-brc.org) is a comprehensive resource supporting research on bacterial and viral pathogens. It currently hosts over 14 million publicly available genomes and 33 high-throughput bioinformatic analysis services with numerous visual analytic tools allowing researchers to analyze their private data, generate comparisons with public data, and share data and results with colleagues. In recent years, the BV-BRC has added several new analysis services to support rapid comparative genomics and epidemiological analysis, viral genome assembly and annotation, viral subspecies classification, wastewater analysis, and molecular docking. In addition, several existing services have been updated to incorporate state-of-the-art tools, including assembly, annotation, taxonomic classification, metagenomic read mapping, and RNA-seq analysis. A new tool, called BV-BRC Copilot, provides an AI-powered natural-language interface that combines large language models with retrieval-augmented generation to guide users through data exploration, analysis workflows, and knowledge integration. With expanded outbreak tracking pages, training and educator engagement, and continued development of novel AI-driven analytics, BV-BRC continues to provide a unified resource to meet the evolving needs of the global research community.

9 August 2021
Verified
Conference Paper
Open access
ASAymen Al Saadi
Aymen Al Saadi
DADario Alfe
Dario Alfe
YBYadu Babuji
Yadu Babuji
ABAgastya Bhati
Agastya Bhati
BBBen Blaiszik
Ben Blaiszik
JYJunqi Yin
Junqi Yin
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2–3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silico methodologies need to be improved both to select better lead compounds, so as to improve the efficiency of later stages in the drug discovery protocol, and to identify those lead compounds more quickly. No known methodological approach can deliver this combination of higher quality and speed. Here, we describe an Integrated Modeling PipEline for COVID Cure by Assessing Better LEads (IMPECCABLE) that employs multiple methodological innovations to overcome this fundamental limitation. We also describe the computational framework that we have developed to support these innovations at scale, and characterize the performance of this framework in terms of throughput, peak performance, and scientific results. We show that individual workflow components deliver 100 × to 1000 × improvement over traditional methods, and that the integration of methods, supported by scalable infrastructure, speeds up drug discovery by orders of magnitudes. IMPECCABLE has screened ∼ 1011 ligands and has been used to discover a promising drug candidate. These capabilities have been used by the US DOE National Virtual Biotechnology Laboratory and the EU Centre of Excellence in Computational Biomedicine.

5 July 2021
Verified
Conference Paper
Open access
HLHyungro Lee
Hyungro Lee
AMAndre Merzky
Andre Merzky
LTLi Tan
Li Tan
MTMikhail Titov
Mikhail Titov
MTMatteo Turilli
Matteo Turilli
SJShantenu Jha
Shantenu Jha
COVID-19 has claimed more than 2.7 × 106 lives and resulted in over 124 × 106 infections. There is an urgent need to identify drugs that can inhibit SARS-CoV-2. We discuss innovations in computational infrastructure and methods that are accelerating and advancing drug design. Specifically, we describe several methods that integrate artificial intelligence and simulation-based approaches, and the design of computational infrastructure to support these methods at scale. We discuss their implementation, characterize their performance, and highlight science advances that these capabilities have enabled.